Effect of recombinant insulin-like growth factor-1 treatment on short-term linear growth in a child with Majewski osteodysplastic primordial dwarfism type II and hepatic insufficiency.

Abstract

We report the case of a boy affected by severe intrauterine and postnatal growth retardation, microcephaly, facial dysmorphisms and postnecrotic cirrhosis, diagnosed at birth as having Seckel syndrome, and subsequently confirmed as Majewski osteodysplastic primordial dwarfism type II (MOPD II) on the basis of clinical and radiological features of skeletal dysplasia. At our observation (6 years 7 months) he presented height -10.3 standard deviation score (SDS), weight -22.1 SDS, head circumference -8 SDS, delayed bone age of 4 years with respect to chronological age. In consideration of the low levels of insulin-like growth factor-1 (IGF-1) as well as of hepatic insufficiency, we started the treatment with recombinant human IGF-1 (rhIGF-1) at the dose of 0.04 mg/kg in 2 doses/day, with an increase of 0.04 mg/kg after 1 week until the maximum dose of 0.12 mg/kg. We observed an early response to rhIGF-1 treatment, with a shift of height velocity from 1.8 cm/year (-4.6 SDS) at 4 cm/year (-1.9 SDS), and an increase in bone age of 1.5 years during the first 6 months. rhIGF-1 treatment does not seem to be able to replace the physiological action of IGF-1 in patients with MOPD II and hepatic insufficiency, however, it seems to preserve the typical growth pattern of MOPD II patients, avoiding a further widening of the growth deficiency in these subjects.

• Authors: Maria Felicia Faienza, Angelo Acquafredda, Mariangela D'Aniello, Lucia Soldano, Flaviana Marzano, Annamaria Ventura, Luciano Cavallo
• Journal: Journal of pediatric endocrinology & metabolism : JPEM (J Pediatr Endocrinol Metab) Vol. 26 Issue 7-8 Pg. 771-4 ( 2013) ISSN: 0334-018X [Print] Germany
• PMID: 23612698 (Publication Type: Journal Article)

Chemical References

• Recombinant Proteins
• Insulin-Like Growth Factor I

Topics

• Body Height (drug effects)
• Body Weight (drug effects)
• Child
• Dwarfism (drug therapy, physiopathology)
• Fetal Growth Retardation (drug therapy, physiopathology)
• Hepatic Insufficiency (drug therapy, physiopathology)
• Humans
• Insulin-Like Growth Factor I (therapeutic use)
• Male
• Microcephaly (drug therapy, physiopathology)
• Osteochondrodysplasias (drug therapy, physiopathology)
• Recombinant Proteins (therapeutic use)